Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties
Open Access
- 14 May 2024
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 242 (7) , 1481-1506
Abstract
Recent research with classic psychedelics suggests significant therapeutic potential, particularly for neuropsychiatric disorders. A mediating influence behind symptom resolution is thought to be the personal insight – at times, bordering on the mystical – one acquires during the acute phase of a psychedelic session. Indeed, current clinical trials have found strong correlations between the acute subjective effects (ASE) under the influence of psychedelics and their enduring therapeutic properties. However, with potential barriers to widespread clinical implementation, including the healthcare resource-intensive nature of psychedelic sessions and the exclusion of certain at-risk patient groups, there is an active search to determine whether ASE elimination can be accompanied by the retention of persisting therapeutic benefits of these class of compounds. Recognizing the aberrant underlying neural circuitry that characterizes a range of neuropsychiatric disorders, and that classic psychedelics promote neuroplastic changes that may correct abnormal circuitry, investigators are rushing to design and discover compounds with psychoplastogenic, but not hallucinogenic (i.e., ASE), therapeutic potential. These efforts have paved the discovery of ‘non-psychedelic/subjective psychedelics’, or compounds that lack hallucinogenic activity but with therapeutic efficacy in preclinical models. This review aims to distill the current evidence – both clinical and preclinical – surrounding the question: can the ASE of classic psychedelics be dissociated from their sustained therapeutic properties? Several plausible clinical scenarios are then proposed to offer clarity on and potentially answer this question.Keywords
Funding Information
- National Institute on Alcohol Abuse and Alcoholism (AA028968, AA029258)
- National Institute on Aging (AG072898)
This publication has 158 references indexed in Scilit:
- Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive EpisodesJAMA Psychiatry, 2024
- Single-Dose Psilocybin Treatment for Major Depressive DisorderJAMA, 2023
- Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use DisorderJAMA Psychiatry, 2022
- Psychedelics in the Treatment of Headache and Chronic Pain Disorders2022
- Psilocybin for the Treatment of Obsessive-Compulsive Disorders2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive DisorderJAMA Psychiatry, 2021
- Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates2017
- Head‐twitch response in rodents induced by the hallucinogen 2,5‐dimethoxy‐4‐iodoamphetamine: a comprehensive history, a re‐evaluation of mechanisms, and its utility as a modelDrug Testing and Analysis, 2012
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage CancerArchives of General Psychiatry, 2011
- Implications of LSD and experimental mysticismJournal of Religion and Health, 1966